A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Stephen Salloway(Providence College), Pierre N. Tariot(Banner Health), Ron Keren(Butler Hospital), C H van Dyck(Butler Hospital), Anton P. Porsteinsson(University of Rochester), Jesse M. Cedarbaum(Butler Hospital), Menghis Bairu(Butler Hospital), Douglas L. Arnold(McGill University), Gerald Crans(Eli Lilly (United States)), Gráinne Quinn(Butler Hospital), S. Gilman(Sahlgrenska University Hospital), C. Hernandez(Butler Hospital), Aleksandra Pastrak(Butler Hospital), E. Liang(Butler Hospital), Reisa A. Sperling(Harvard University), Susan Abushakra(Framingham State University)
Cited by 255
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k